Towards the Validation of a New Blood Biomarker for the Early Diagnosis of Parkinson's Disease

NCT05385315 · tracked via the Priya Life Science France tracker

Sponsor

University Hospital, Grenoble

Phase

Observational

Started

2022-10-13

Last updated

2024-12-11

Condition(s) studied

Parkinson Disease

Study summary

The investigators have recently discovered a metabolic biomarker which predicts Parkinson's disease (PD) at the early stages in patients and in animal models. The aim of BIOPARK is to investigate how the biomarker evolves in advanced PD stage, when diagnosis confirmation is higher, an in de novo PD patients who come from a different geographical area than those of the publication (since it is known that the metabolome is largely influenced by lifestyle). They will also evaluate if the biomarker is able to distinguish patients with a parkinsonian syndrome often confused with parkinson's disease, i.e. Multiple System Atrophy (MSA).

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Patients with de novo Parkinson's disease, without dopaminergic treatment * Patients with advanced Parkinson's disease (\> 5years) with dopaminergic treatment * Patients with multiple system atrophy Exclusion Criteria: * Patients with deep brain stimulation * Other neurodegenerative diseases * patients protected by french law (pregnant or lactating women, prisoners, ...)

Primary outcome measure(s)

validation of the biomarker in advanced stage PD — 2 years
The main objective of the project is to evaluate whether classification with the biomarker is consistent with the diagnosis in a cohort of parkinsonian patients with high diagnostic confirmation, i.e. patients treated with L-Dopa for over 5 years

Trial sites (1)

Facility	City	Region	Status
CHU Grenoble Alpes	Grenoble	France	Recruiting

More University Hospital, Grenoble trials in France

Down Syndrome, Physical Activity and Sleep Apnea Recruiting

Osteosynthesis of Fibula Fractures With a Locked Thin Plate Starting soon

Efficacy of Morphine in Reducing the Rate of Early Non-Invasive Ventilation Failure in Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Phase I/IIa Recruiting

Preparation and Feasibility of Exams for Expected Studies Recruiting

Effectiveness of a Communication Training Program in Improving the Handling of Calls for Suspected Cardiac Arrest at SAMU-Centre 15. Starting soon

Other trials for the same condition

To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications Active, not recruiting

Deep Brain Stimulation (DBS) Retrospective Outcomes Study Recruiting

Pain in Parkinson's Disease: Exploration of the Serotonin System in Positron Emission Tomography (PET [18F]-MPPF) Recruiting

Clinical Evaluation of A neW Management Strategy for Patients With pArKinson's disEase usiNg an Innovative telemonitorING (AWAKENING) Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05385315 on ClinicalTrials.gov ↗ ← All trials in France